Actavis Puts Greater Emphasis On Branded Rx By Taking Allergan Name
This article was originally published in The Pink Sheet Daily
The growing spec pharma has seen a 300% increase in its branded portfolio revenues since the acquisition of Forest and Warner Chilcott and is honoring the new direction by taking on the name of its most recent acquisition.
You may also be interested in...
The company will move forward with 70 pipeline candidates following the closing of the Allergan merger, Senior VP-Brand R&D David Nicholson said during the company’s first quarter earnings call.
Brent Saunders, who will lead the new Allergan once the merger with Actavis closes, is ready to begin the integration, with an eye toward achieving 80% of the expected $2.3 billion in cost savings 12 months after close.
Before adding Allergan into the mix – and taking on its name – Actavis wants to show investors that it has a solid foundation as a growth pharma with strong brands in GI, CNS and women’s health.